Skip to main content

Table 1 The clinical characteristics of HER2neg and HER2low TNBC patients

From: Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low

Clinical characteristics

TNBC grouping (N = 251)

OR

95% CI

P

HER2neg

HER2low

n = 94 (37.5%)

n = 157 (62.5%)

Age (years)

  

1.97

1.09–3.57

0.03

 < 45

29 (30.9)

29 (18.5)

   

 ≥ 45

65 (69.1)

128 (81.5)

   

Menstrual status

  

0.68

0.39–1.17

0.17

 Pre

59 (62.8%)

112 (71.3%)

   

 Post

35 (37.2%)

45 (28.7%)

   

Lesion

  

0.95

0.57–1.58

0.90

 Left

46 (48.9%)

79 (50.3%)

   

 Others

48 (51.1%)

78 (49.7%)

   

NST

  

0.91

0.54–1.51

0.80

 No

48 (51.1%)

84 (53.5%)

   

 Yes

46 (48.9%)

73 (46.5%)

   

Tumor size

  

1.93

1.04–3.57

0.04

 < 2 cm

26 (27.7%)

26 (16.6%)

   

 ≥ 2 cm

68 (72.3%)

131 (83.4%)

   

Lymph node metastasis

  

1.85

1.10–3.13

0.02

 Negative

45 (47.9%)

52 (33.1%)

   

 Positive

49 (52.1%)

105 (66.9%)

   

Distant metastasis

  

0.85

0.31–2.30

0.8

 Negative

87 (92.6%)

147 (93.6%)

   

 Positive

7 (7.4%)

10 (6.4%)

   

Pathological type

  

1.53

0.85–2.77

0.16

 Ductal

73 (77.7%)

109 (69.4%)

   

 Others

21 (22.3%)

48 (35.5%)

   

Ki67, %

  

5.97

3.16–11.31

< 0.001

 < 30

41 (43.6%)

18 (11.5%)

   

 ≥ 30

53 (56.4%)

139 (88.5%)

   

Histological grade

  

2.68

1.41–5.12

< 0.01

 I/II

79 (84.0%)

104 (66.2%)

   

 III

15 (16.0%)

53 (33.8%)

   
  1. NST, neoadjuvant systemic therapy
  2. P values in bold indicate statistical significance